Disease | N | Age, mean and range (y) | Braak (Tau) | Sex (f/m) | Region | N | Figures |
|---|
AD | 15 | 69 (55–86) | V-VI | 11/4 | EC | 2 | 3 and 4 |
HIP | 2 |
FC | 5 |
TC | 10 |
PSP | 3 | 80 (72–89) | n.d | 1/2 | PUT | 3 |
PD | 3 | 80 (74–90) | 0-II | 0/3 | SN | 3 |
MSA | 3 | 61 (60–62) | n.d | 3/0 | CER | 3 |
CTR | 19 | 74 (49–93) | I-II* | 8/11 | EC | 4 |
HIP | 3 |
TC | 3 |
PUT | 3 |
SN | 3 |
CER | 3 |
- Alzheimer’s disease (AD), Progressive supranuclear palsy (PSP), Parkinson’s disease (PD), Multiple system atrophy (MSA) and control (CTR) brain samples. Four AD patients donated two different brain areas (for details see Additional file 1: Table S1). Old, non-demented controls had neurofibrillary tangles classifying them as Braak I-II. EC: Entorhinal cortex; HIP: Hippocampus; FC: Frontal Cortex; TC: Temporal Cortex; PUT: Putamen; SN: Substantia Nigra; CER: Cerebellum; y: years; f: female; m: male; n.d.: not determined. *Indicated Braak stage (Tau) based on 3 C donors. For detailed description of cohort 1 samples, see Additional file 1: Table S2
